The pulmonary renin-angiotensin system
- PMID: 12570789
- DOI: 10.2174/1381612033455431
The pulmonary renin-angiotensin system
Abstract
The circulating renin-angiotensin system (RAS) has a well-described role in circulatory homeostasis. Recently, local tissue-based RAS have also been described which appear to play a key role in the injury/repair response. The expression of RAS components and the elevation of angiotensin converting enzyme in a number of interstitial lung diseases suggests the existence of a pulmonary RAS and that angiotensin II could mediate, at least in part, the response to lung injury. Activation of a local RAS within the pulmonary circulation and lung parenchyma could influence the pathogenesis of lung injury via a number of mechanisms including an increase in vascular permeability, vascular tone and fibroblast activity, and by reducing alveolar epithelial cell survival. The ability of both ACE inhibitors and angiotensin II receptor antagonists to attenuate experimental lung injury further supports a role for RAS activation and suggests these agents may be useful in the treatment of diffuse parenchymal lung disease. However, further studies are required to delineate the cell types responsible for RAS component expression in the lung and also to identify the key effector molecules of this system. The presence of common polymorphisms in RAS genes and their study in relation to specific physiological phenotypes will aid both our understanding of the role of RAS in the lung and also aid the targeting of future therapies.
Similar articles
-
Manipulating the angiotensin system--new approaches to the treatment of solid tumours.Expert Opin Biol Ther. 2006 Mar;6(3):243-55. doi: 10.1517/14712598.6.3.243. Expert Opin Biol Ther. 2006. PMID: 16503734 Review.
-
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
-
Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.J Mol Cell Cardiol. 2013 Oct;63:98-106. doi: 10.1016/j.yjmcc.2013.07.010. Epub 2013 Jul 22. J Mol Cell Cardiol. 2013. PMID: 23886814 Review.
-
Effects of angiotensin-converting enzyme inhibitors on tissue renin-angiotensin systems.Am J Cardiol. 1992 Oct 8;70(10):12C-19C. doi: 10.1016/0002-9149(92)91353-6. Am J Cardiol. 1992. PMID: 1414888 Review.
-
Tissue renin-angiotensin system: a site of drug action?Annu Rev Pharmacol Toxicol. 1997;37:53-69. doi: 10.1146/annurev.pharmtox.37.1.53. Annu Rev Pharmacol Toxicol. 1997. PMID: 9131246 Review.
Cited by
-
Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial.Ann Intensive Care. 2024 Sep 4;14(1):139. doi: 10.1186/s13613-024-01369-0. Ann Intensive Care. 2024. PMID: 39231898 Free PMC article.
-
Covid-19 and the Renin Angiotensin System: Implications for the Older Adults.J Nutr Health Aging. 2020;24(7):699-704. doi: 10.1007/s12603-020-1403-7. J Nutr Health Aging. 2020. PMID: 32744564 Free PMC article. Review. No abstract available.
-
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.Biochem Pharmacol. 2020 Aug;178:114057. doi: 10.1016/j.bcp.2020.114057. Epub 2020 May 27. Biochem Pharmacol. 2020. PMID: 32470547 Free PMC article. Review.
-
Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.Hypertension. 2009 Aug;54(2):365-71. doi: 10.1161/HYPERTENSIONAHA.108.125468. Epub 2009 Jun 29. Hypertension. 2009. PMID: 19564552 Free PMC article.
-
SARS-CoV-2 associated COVID-19 in geriatric population: A brief narrative review.Saudi J Biol Sci. 2021 Jan;28(1):738-743. doi: 10.1016/j.sjbs.2020.11.001. Epub 2020 Nov 5. Saudi J Biol Sci. 2021. PMID: 33169063 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
